Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MONTRÉAL, 02 août 2022 (GLOBE NEWSWIRE) -- Le CN (TSX : CNR) (NYSE : CNI) a annoncé aujourd’hui une émission publique de titres d’emprunt de 1,5 G$ US composée de 800 M$ US de billets à...
-
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) today announced a public debt offering of US$1.5 billion comprised of US$800 million 3.85% Notes due 2032 and US$700 million...
-
HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) announced today that it completed its previously announced private placement of...
-
Tous les montants sont en dollars canadiens à moins d’indication contraire. QUÉBEC, 02 août 2022 (GLOBE NEWSWIRE) -- (TSX : HEO) – Veuillez prendre note qu’une erreur s’est glissée dans...
-
All amounts are in Canadian dollars unless otherwise stated. QUEBEC CITY, Aug. 02, 2022 (GLOBE NEWSWIRE) -- (TSX: HEO) – Please note that an error has crept into the press release issued earlier...
-
ROWAYTON, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eaton Partners, one of the largest placement agents and financial advisory firms and a wholly-owned subsidiary of Stifel Financial Corp. (NYSE:...
-
MCLEAN, Va., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today announced that it has commenced a fixed-price cash tender offer (the “Offer”) for the purchase of any and all of the...
-
SALT LAKE CITY, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nav Technologies, Inc. (“Nav”), a simple and intelligent financing platform for small businesses, announced today English for a Lifetime as the...
-
NEWPORT BEACH, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pelorus Equity Group (“Pelorus,” or “the Company”), the leading provider of commercial real estate loans for the cannabis sector, is pleased...
-
There is No FDA-Approved Product for Cocaine Intoxication TNX-1300 Has Been Granted Breakthrough Therapy Designation by the FDA Phase 2 Single-Blind, Placebo-Controlled, Potential Pivotal Study...